Funds to support innovation and answers in WA state research institutions Sept. 21, 2023 For Immediate Release Molly O’Connor, CEO(206) 490-0878; molly.oconnor@rivkin.org SEATTLE – Washington state ovarian cancer researchers will have an extra $1M in grant funding over the next two years thanks to a pioneering public-private partnership between the Rivkin Center for Ovarian Cancer […]
Read More
To say that a cure for ovarian cancer, or any cancer for that matter, is the “holy grail” of cancer research is like saying the sky is blue. We all know a cure is the goal. If a cure is the goal, then improved detection, new prevention methods, and new treatments are the low-hanging fruit. […]
Read MoreThe Rivkin Center is proud to announce that we have awarded $540,000 in ovarian cancer research grants to six scientists from the US and abroad. While the pandemic continues to create challenges for small nonprofits, the Rivkin Center is thankful to our community of supporters who give us the ability to fund critical, life-saving research. […]
Read MoreThe Rivkin Center is proud to announce that the organization has awarded $345,000 in ovarian cancer research grants to four scientists from the United States and abroad. Although 2020 proved to be a challenging year for small nonprofits, the Rivkin Center is thankful that we are still able to fund critical, life-saving research, thanks to […]
Read More
The Rivkin Center is proud to announce that we have awarded $810,000 in ovarian cancer research grants to nine scientists across the globe.
Read More
We’re excited to share results of three recent studies that provide hope for women with newly diagnosed ovarian cancer. The studies, reported at the annual meeting of the European Society of Medical Oncology and two of which were published in the New England Journal of Medicine recently, show that three different types of PARP inhibitors […]
Read More
Seattle, WA: The Rivkin Center, a Seattle-based 501(c)(3), announced that they have awarded $1.455 million in ovarian cancer research grants to sixteen scientists across the globe. The amount funded was nearly a 20% increase over last year. The Rivkin Center’s unique approach to funding provides researchers leverage to access larger pots of federal funds for […]
Read More
The Federal Drug Administration (FDA) made an exciting announcement this week with the first approval for PARP inhibitors to be used for patients following their initial diagnosis and treatment to reduce the risk of recurrence. The FDA approved the use of the PARP inhibitor olaparib (Lynparza®) for frontline maintenance therapy for advanced epithelial ovarian, fallopian […]
Read More
You may have read in recent news that a new research study found that daily, low-dose aspirin may lower a woman’s risk of developing ovarian cancer. So does that mean you should start — or change — your aspirin regimen? Dr. Nora Disis, our Medical and Scientific Director and the Director of the University of […]
Read More
PARP inhibitors represent an important new class of anticancer agents that are having a major impact on ovarian cancer treatment. These drugs target vulnerabilities in DNA damage response and repair pathways especially in cancer cells that have defects in BRCA and related genes. In an important clinical development announced April 6, 2018, the FDA expanded […]
Read More